Compare BioNTech SE - ADR (BNTX) vs Sunrun Inc (RUN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Sunrun Inc — how do they compare? BioNTech SE - ADR trades at $89.89 (market cap $22.86B), while Sunrun Inc trades at $12.83 (market cap $3.05B). The key difference: BioNTech SE - ADR is far larger — about 7.5× Sunrun Inc's market cap, and Sunrun Inc is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| BNTX | RUN | |
|---|---|---|
Market Cap | $22.86B | $3.05B |
Sector | Health | Technology |
52-Week High | $119.34 | $21.41 |
52-Week Low | $83.89 | $9.07 |
Enterprise Value | $6.53B | $17.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
Sunrun (RUN) trades at $12.41, down 0.48% on the day, with technical indicators showing a bearish trend despite recent earnings beats. The company reported strong profitability with a 17.88% net income margin and ROE of 19.06%, while valuation metrics like P/E of 6 and P/B of 0.91 suggest potential undervaluation. Recent news highlights a major partnership with Tesla and Renew Home for a 16-gigawatt virtual power plant, driving investor interest in grid-support initiatives tied to AI data center demand.
The stock presents a mixed outlook: analyst consensus is strongly bullish with a $17.09 price target (62% buy ratings), but negative operating cash flow and high debt-to-asset ratio of 70.76% pose risks. Growth catalysts include expanding revenue and margin trends, though execution on new ventures and macroeconomic pressures remain key watchpoints for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Sunrun Inc
Sunrun Inc. is one of the largest residential solar, battery storage, and energy services companies in the United States. The company provides solar panel installations, battery backup systems, and energy management solutions to homeowners. Sunrun primarily uses a solar-as-a-service model, offering customers solar leases and power purchase agreements (PPAs), which allow homeowners to adopt solar energy with little to no upfront cost. The company's mission is to create a planet run by the sun.
Read more on RUN →
